Andere talen Virax Biolabs Group Limited

Aandelen

VRAX

KYG9495L1251

Vertraagde tijd Nasdaq Andere beurzen 17:48:33 25-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,6959 ^USD	+4,87%		+2,38%	-52,34%

14:00	Virax Biolabs lanceert Portfolio van Immuunprofileringsoplossingen die Adaptieve Immuniteit in Post-Virale Syndromen evalueren op ESCMID Global 2024	CI
12/01	Virax Biolabs Group Limited rapporteert resultaten voor het halfjaar dat eindigde op 30 september 2023	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Virax Biolabs : Launches Portfolio of Immune Profiling Solutions Evaluating Adaptive Immunity in Post-Viral Syndromes at ESCMID Global 2024 - Form 6-K	14:06
Virax Biolabs Launches Portfolio of Immune Profiling Solutions Evaluating Adaptive Immunity in Post-Viral Syndromes at ESCMID Global 2024	14:00
Virax Biolabs to Participate at ESCMID Global 2024	17/04
Virax Biolabs : to Participate at ESCMID Global 2024 - Form 6-K	16/04
Virax Biolabs : Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price Deficiency - Form 6-K	15/03
Virax Biolabs Group Limited Reports Earnings Results for the Half Year Ended September 30, 2023	12/01
Virax Biolabs Forges Strategic Research Collaboration with University of Manchester and the Northern Care Alliance Foundation Trust to Enhance Understanding of Immune Responses in COVID Patients	22/12
Virax Biolabs Group Limited Forges Strategic Research Collaboration with University of Manchester and Northern Care Alliance Foundation Trust to Enhance Understanding of Immune Responses in COVID Patients	21/12
Virax Biolabs Group Limited Announces 1-for-10 Share Consolidation	15/12
Top Premarket Gainers	12/12
Virax Biolabs : Notice of 2023 Annual General Meeting of Shareholders To Be Held on - Form 6-K	08/11
Virax Biolabs : CLAWBACK POLICY - Form 6-K	31-10-23
Virax Biolabs Group Limited announced that it has received $2.15 million in funding	17-10-23
Virax Biolabs Group Limited announced that it expects to receive $2.15 million in funding	12-10-23
Virax Biolabs Group Announces Early-Access Program Launch of Research Use Only ViraxImmune Product and Hosts Webinar	13-09-23
Virax Biolabs : Announces Early-Access Program Launch of Research Use Only ViraxImmune Product and Hosts Webinar - Form 6-K	12-09-23
Virax Biolabs Group Appoints Dr. Nigel McCracken as Chief Operating Officer to Oversee Growth Momentum	04-09-23
Virax Biolabs Group Names Nigel McCracken Operating Chief.	01-09-23
Virax Biolabs Group Limited Announces Management Changes	01-09-23
Nasdaq Approves 180-Day Extension for Virax Biolabs Group to Meet Minimum $1 Bid	04-08-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Virax Biolabs Group Limited

Aandelen

VRAX

KYG9495L1251

Andere talen

Filters